Trial Profile

A Multi-Center Phase II Study Testing the Activity of Olaparib and AZD6738 (ATR Inhibitor) in Metastatic Castration-Resistant Prostate Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 31 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ceralasertib (Primary) ; Olaparib (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms TRAP

Most Recent Events

28 Mar 2025 Planned End Date changed from 1 Jan 2027 to 1 Aug 2028.
22 Jun 2023 Planned End Date changed from 1 Feb 2027 to 1 Jan 2027.
09 Jan 2023 Planned End Date changed from 1 Nov 2026 to 1 Feb 2027.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com